Univariate analysis of risk factors for immunomodulator (IM) resistance
| IM responsive (n=21) | IM resistant (n=15)† | p Value* | |
|---|---|---|---|
| Age >65 years at diagnosis | 10 (48) | 8 (53) | 0.61 |
| IgG4 >ULN | 18 (86) | 13 (87) | 0.68 |
| IgG4 >2×ULN | 7 (33) | 6 (40) | 0.81 |
| Initial treatment by surgery | 3 (14) | 0 | 0.16 |
| Diffuse pancreatic enlargement at presentation | 13/19 (68) | 7/13 (54) | 0.45 |
| Other organ involvement | |||
| OOI ever | 12 (57) | 14 (93) | 0.03 |
| IgG4-relatedSC at presentation | 7 (33) | 7 (47) | 0.34 |
| OOI (other than IgG4-related SC) | 6 (29) | 12 (80) | <0.01 |
| Retroperitoneal fibrosis | 0 | 7 (47) | <0.01 |
| >6 months duration from diagnosis to IM initiation | 15 (71) | 8 (53) | 0.20 |
Data presented as n (%), unless otherwise indicated.
*p Values were calculated using the log-rank test from Kaplan–Meier analyses.
†IM resistant column does not include the two patients who did not tolerate treatment.
OOI, other organ involvement; SC, sclerosing cholangitis; ULN, upper limit of normal.